Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME2PFQ)

Drug Name

TA-106 Drug Info

Synonyms

FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement factor B (CFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Iptacopan	DM9EZM0	Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[2]
LPN023	DM7BN5W	IgA nephropathy	MF8Y	Phase 2	[3]
RG6299	DMVJL8W	Geographic atrophy	9B75	Phase 2	[4]
SAR443809	DMSUQTW	Discovery agent	N.A.	Phase 1	[5]
CAB-2	DMQ4HUA	Coronary artery disease	BA80	Discontinued in Phase 1	[6]
PMID19743866C51	DMTX0ZJ	Discovery agent	N.A.	Investigative	[7]
NM-9308	DMC89HI	Age-related macular degeneration	9B75.0	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339).
2	Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.
3	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166.
4	Clinical pipeline report, company report or official report of Roche
5	Clinical pipeline report, company report or official report of Sanofi
6	A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation. 2002 Mar;9(2):125-34.
7	Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem. 2009 Oct 8;52(19):6042-52.